שווי פעילות לרווח לפני ריבית, מסים ופחת: TherapeuticsMD Inc (TXMD)

The current quotes for TherapeuticsMD, Inc. (TXMD) displayed on the GURU.Markets platform show an EV/EBITDA of 0.00. Sales stability is driven by female consumer loyalty to proven hormonal product lines. The company achieves broad audience reach by developing products for various life stages, including menopause. Financial stability is supported by a lack of debt, although revenue relies on licensing royalties and patent protection.

The EV/EBITDA multiple compares the total enterprise value of a business with its operating profit before depreciation, taxes, and interest, allowing for an asset valuation independent of capital structure. By analyzing the change in the EV/EBITDA value over time, a TherapeuticsMD, Inc. (TXMD) investor can determine a fair share price, given that the diversification of women's health medications and licensing contracts stabilize the company's cash flows.